SCHEMBL4769719

SCHEMBL4769719

CS(=O)(=O)N(Cc1ccccc1Cl)c1ccc(N(C=O)Cc2ccc(OCCO)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.43
GAA P10253 1/20 0.42
PTPN1 P18031 5/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
THRB P10828 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
PTPN2 P17706 1/20 0.38
PTPN6 P29350 1/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778588 0.80 GAA (0.65) POLBGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4777339 0.80 GAA (0.56) GAAALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL4769726 0.80 POLB (0.44) POLBGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4775060 0.79 GAA (0.39) POLBGAAPTPN1ALDH1A1MAPT
SCHEMBL5571164 0.76 GAA (0.44) POLBGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4776386 0.76 CYP2A13 (0.46) GAAALDH1A1SMN1; SMN2LMNA
SCHEMBL4771377 0.74 GAA (0.40) POLBGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4776710 0.74 GAA (0.43) POLBGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4776590 0.74 GAA (0.42) POLBGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4773507 0.73 GAA (0.42) GAAALDH1A1MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 POLB 292/4885GAA 466/4885PTPN1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.